Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Role and timing of chromosome deletions in multiple myeloma

Stéphane Minvielle, Eric Letouzé

Blood (2024) 144 (7): 688–689.

https://doi.org/10.1182/blood.2024025269

Published: 2024

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Blood (2023) 142 (18): 1543–1555.

https://doi.org/10.1182/blood.2023020211

Published: 2023

Includes: Supplemental data

Journal Articles

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2023) 141 (14): 1724–1736.

https://doi.org/10.1182/blood.2022017094

Published: 2023

Includes: Supplemental data

Journal Articles

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Romane Durand, Domitille Costes-Tertrais, Geraldine Descamps, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Elise Douillard, Jennifer Derrien, Celine Bellanger, David Chiron, Stephane Minvielle, Cyrille Touzeau, Philippe Moreau, Martine Amiot, Patricia Gomez-Bougie, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 4198–4199.

https://doi.org/10.1182/blood-2022-155862

Published: 2022

Journal Articles

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Salomé Decombis, Celine Bellanger, Yannick Le Bris, Delphine Boulet, Jane Jardine, Christelle Dousset, Audrey Ménard, Charlotte Kervoelen, Elise Douillard, Philippe Moreau, Stephane Minvielle, Agnes Moreau-Aubry, Benoit Tessoulin, Nicolas Bidère, Steven Le Gouill, Catherine Pellat-Deceunynck, David Chiron

Blood (2022) 140 (Supplement 1): 2044–2045.

https://doi.org/10.1182/blood-2022-157694

Published: 2022

Journal Articles

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Parth Shah, Anil Aktas-Samur, Mariateresa Fulciniti, Raphael Szalat, Masood A. Shammas, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil C. Munshi, Mehmet K. Samur

Blood (2021) 138 (Supplement 1): 461.

https://doi.org/10.1182/blood-2021-151647

Published: 2021

Journal Articles

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Blood (2021) 137 (9): 1192–1195.

https://doi.org/10.1182/blood.2020008346

Published: 2021

Includes: Supplemental data

Journal Articles

Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study

Jean-Baptiste Alberge, Bastien Jamet, Clement Bailly, Cyrille Touzeau, Jonathan Cruard, Thomas Carlier, Caroline Bodet-Milin, Michel Cherel, Philippe Moreau, MD, Stephane Minvielle, Francoise Kraeber-Bodere

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-140235

Published: 2020

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 686.

https://doi.org/10.1182/blood-2019-131981

Published: 2019

Journal Articles

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

Tessa Han, Stephane Minvielle, PhD, Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Florence Magrangeas, PhD, Paul G. Richardson, MD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Hervé Avet-Loiseau, MD PhD, Giovanni Parmigiani, PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4348.

https://doi.org/10.1182/blood-2019-130343

Published: 2019

Journal Articles

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Anil Aktas Samur, PhD, Mehmet Kemal Samur, PhD, Stephane Minvielle, PhD, Florence Magrangeas, PhD, Masood A. Shammas, PhD, Mariateresa Fulciniti, PhD, Michel Attal, MD PhD, Philippe Moreau, Kenneth Anderson, MD, Giovanni Parmigiani, Hervé Avet-Loiseau, MD PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2018-99-120101

Published: 2018

Journal Articles

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Blood (2018) 132 (Supplement 1): 4099.

https://doi.org/10.1182/blood-2018-99-113303

Published: 2018

Journal Articles

The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis

Francesco Maura, Daniel Leongamornlert, BS, Nicos Angelopoulos, PhD, Kevin J Dawson, Mehmet Kemal Samur, PhD, Raphael Szalat, MD, Yu-Tzu Tai, PhD, Stephane Minvielle, PhD, Florence Magrangeas, Philippe Moreau, Paolo Corradini, MD, Kenneth C. Anderson, MD, Hervé Avet-Loiseau, MDPhD, Peter J. Campbell, PhD, Nikhil Munshi, MD, Niccolò Bolli

Blood (2018) 132 (Supplement 1): 109.

https://doi.org/10.1182/blood-2018-99-112420

Published: 2018

Journal Articles

Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Chandraditya Chakraborty, PhD, Raphael Szalat, MD, Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, Masood A. Shammas, PhD, Paul Richardson, Florence Magrangeas, PhD, Stephane Minvielle, PhD, Philippe Moreau, Michel Attal, Anjan Thakurta, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, Hervé Avet-Loiseau, MDPhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 190.

https://doi.org/10.1182/blood-2018-190

Published: 2018

Journal Articles

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Yannick LE Bris, MDPharmD, Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Benoit Tessoulin, MD, Florence Magrangeas, PhD, Marie-Helene Delfau, MD, Catherine Thieblemont, MD, Lucie Oberic, MD, Krimo Bouabdallah, MD, Emmanuel Gyan, MD PhD, David Chiron, PhD, Catherine Pellat-deceunynck, PhD, Mary Callanan, PhD, Stephane Minvielle, PhD, Marie C Bene, PharmSci, PhD, Olivier Hermine, MD PhD, Steven Le Gouill, MD PhD

Blood (2018) 132 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2018-99-113268

Published: 2018

Journal Articles

The Genomic Landscape of Multiple Myeloma Complex Structural Variations

Blood (2017) 130 (Supplement 1): 330.

https://doi.org/10.1182/blood.V130.Suppl_1.330.330

Published: 2017

Journal Articles

Biological and Prognostic Impact of Apobec-Induced Mutations in the Spectrum of Plasma Cell Dyscrasias

Blood (2017) 130 (Supplement 1): 1771.

https://doi.org/10.1182/blood.V130.Suppl_1.1771.1771

Published: 2017

NARROW

Role and timing of chromosome deletions in multiple myeloma

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis

Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

The Genomic Landscape of Multiple Myeloma Complex Structural Variations

Biological and Prognostic Impact of Apobec-Induced Mutations in the Spectrum of Plasma Cell Dyscrasias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only